DDInter948 DDInter612
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Sonidegib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Duvelisib may lead to a major life threatening interaction when taken with Sonidegib
Duvelisib may lead to a major life threatening interaction when taken with Upadacitinib